Retrophin, Inc. (RTRX): Alvin Shih , EVP of Research & Development of Retrophin, Inc. sold 8,750 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 2, 2016 to the Securities and Exchange Commission. The shares were sold at $17.75 per share for a total value of $155,283.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 7, 2016, Jeffrey A Meckler (director) purchased 5,000 shares at $15.31 per share price.On Mar 1, 2016, Alvin Shih (EVP of Research & Development) sold 8,750 shares at $14.35 per share price.Also, On Nov 12, 2015, Steve Aselage (Chief Executive Officer) sold 60,000 shares at $18.75 per share price.On Nov 4, 2015, Jensen Margaret E Valeur (General Counsel) sold 50,000 shares at $20.75 per share price.
Retrophin Inc: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Retrophin Inc which led to swings in the share price. The shares opened for trading at $17.7 and hit $17.96 on the upside , eventually ending the session at $17.8, with a gain of 0.11% or 0.02 points. The heightened volatility saw the trading volume jump to 4,29,131 shares. The 52-week high of the share price is $37.04 and the company has a market cap of $653 M . The 52-week low of the share price is at $11.6.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.